The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
Official Title: PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
Study ID: NCT03740893
Brief Summary: PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase IIa trial comprising multiple non-comparative treatment cohorts with patient allocation via randomisation. The trial consists of two parts: a post-neoadjuvant chemotherapy, preoperative WOP component (PART 1); and a post-operative component (PART 2). PHOENX aims to assess whether short exposure to a DNA damage response (DDR) inhibitor and/or anti-PD-L1 immunotherapy in a preoperative WOP in patients with post-NACT high residual disease, generates a signal of anti-tumour biological activity within residual disease tissue.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom
King's College Hospital, London, England, United Kingdom
Christie Hospital NHS Trust, Manchester, England, United Kingdom
Belfast City Hospital, Belfast, Northern Ireland, United Kingdom
Velindre Cancer Center at Velinde Hospital, Cardiff, Wales, United Kingdom
Queen Elizabeth Hospital, University Hospitals Birmingham NHS Trust, Birmingham, , United Kingdom
Guy's and St Thomas' Hospital NHS Foundation Trust, London, , United Kingdom
Weston Park Hospital, Sheffield, , United Kingdom
Name: Andrew Tutt
Affiliation: Institute of Cancer Research, United Kingdom
Role: PRINCIPAL_INVESTIGATOR